Dr. Schmitt on a Novel Treatment Approach to Hodgkin Lymphoma

Clemens A. Schmitt, MD, director and professor at Berlin School of Integrative Oncology, discusses a conceptually novel treatment approach to classical Hodgkin lymphoma.

In general, Hodgkin lymphoma is a very treatable disease, explains Schmitt. However, this may no longer apply to patients who are primarily refractory or have relapsed after standard treatment.

Schmitt investigated a preclinical study considering that a genetic or pharmacological approach to restore the B-cell phenotype of Hodgkin lymphoma cells could be therapeutic or could open the door for using treatment components such as antibodies or signaling inhibitors.